
Switching to intravitreal faricimab injections (IFIs) in patients with treatment-resistant neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) showed significant clinical benefits in a treat-and-extend protocol. The treatment interval extended from an average of 37.6 ± 10.8 days to 45.2 ± 16.6 days (p = 0.0016). Spectral-domain OCT results revealed a 35% fluid-free rate among patients, with a significant reduction in central subfield thickness from 327.2 ± 89.1 μm to 294.8 ± 86.5 μm (p = 0.0294). However, no notable differences were observed in best-corrected visual acuity, intraocular pressure, pigment epithelium detachment presence or height.
Like
Save
Share